On August 14, 2026, it received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American (the "Exchange") under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide (the "Company Guide"). The non-compliance results from the Company’s failure to timely file its Annual Report on Form 10-K for the year ended April 30, 2026 (the "Delinquent Report") by the filing due date of August 13, 2026 (the "Filing Delinquency").

On August 19, 2026, the Company filed with the SEC its Form 10-K for the year ended April 30, 2026 and cured the Filing Delinquency.

In accordance with Section 1007 of the Company Guide, the Company had six months from the date of the Filing Delinquency, or until February 13, 2027 (the "Initial Cure Period"), to file the Form 10-K with the SEC. If the Company had failed to file the Form 10-K during the Initial Cure Period, the Exchange could have, in its sole discretion, provided an additional six-month cure period (the "Additional Cure Period"). The Company has regained compliance with the Exchange’s continued listing standards during the Initial Cure Period by filing the Form 10-K with the SEC.